SimpleAdvanced       Search Search 152 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
2017-3533 A Phase III, open-label, controlled, randomized, multicenter study evaluating the efficacy and safety of StrataGraft® skin tissue in promoting autologous skin tissue regeneration of complex skin defects due to thermal burns that contain intact dermal elements and for which excision and autografts are clinically indicated Open
2017-3807 A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease Open
2017-3817 WIRB #35 A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF). Open
2017-3818 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF REPEATED ADMINISTRATIONS OF NUROWN® (AUTOLOGOUS MESENCHYMAL STEM CELLS SECRETING NEUROTROPHIC FACTORS) IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) Open
2017-3897 A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cells (LMSCs) Infusion in Patients with Aging Frailty Open
2017-3946 Short- and Long-term Effects of Rituximab Therapy on B cell subsets, Immunoglobulins isotypes and subclasses, Specific Antibodies, and infectious complications: Effect of Immunoglobulin Therapy Open
2017-3975 A Prospective Non-interventional Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy Open
2017-4101 A Phase 2, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects with Generalized Myasthenia Gravis Open
2017-4113 Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt Open
2018-4192 An Open-Label Study in Subjects with Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment Open
2018-4223 EFFICACY, SAFETY, AND TOLERABILITY OF FOSMETPANTOTENATE (RE-024), A PHOSPHOPANTOTHENATE REPLACEMENT THERAPY, IN PATIENTS WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (PKAN): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION Open
2018-4282 Protocol I5T-MC-AACG(a) Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer’s Disease Open
2018-4306 A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT™|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures. Open
2018-4307 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis (OSTRO) Open
2018-4455 A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA Open
ALLIANCE-A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
ALLIANCE-A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC) Open
ALLIANCE-A071601 (CIRB) Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Open
ALLIANCE-A221101 ALLIANCE-A221101-A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma Open
ALLIANCE-A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
ECOG-E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Open
ECOG-E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Open
ECOG-EAF151 Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma Open
ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
GOG-0237 Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Open
GOG-0263 Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Open
GOG-0278 Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer Open
GOG-0279 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Open
GOG-0724 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy Open
GOG-3015 A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
GOG-3016 An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma Open
NRG-BN003 Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma Open
NRG-BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Open
NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Open
NSABP-B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
RTOG-3503 Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Open
SWOG-N1048 A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Open
SWOG-S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III (Paces) Open
SWOG-S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
SWOG-S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy Open
SWOG-S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
SWOG-S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-Refractory Metastatic Colorectal Cancer (mCRC) Open
UCI-01-61 A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer Open
UCI-03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-08-51 Near Infrared Optical Coherence Tomography of the Upper Aero-digestive Tract Open
UCI-09-17 Biology of Human Melanocytes and Keratinocytes Open
UCI-10-24 ATHENA Breast Health Network Open
UCI-11-16 [DATABASE REVIEW] Data Linkage Study of Ship Yard Workers to Monitor Health Outcomes Open
UCI-11-19 Evaluation of Peritumoral Renal Adipose Tissue to Renal Cancer Aggressiveness Open
UCI-11-30 Skin Imaging with Technologies in Development Open
UCI-12-18 (BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments Open
UCI-12-40 Atlas Colorectal Health Network Open
UCI-13-02 Assessing Fitness, Physical Activity and Leukocyte Genomic Response to Exercise in Acute Lymphoblastic Leukemia (ALL) Patients in Remission Open
UCI-14-03 Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm Open
UCI-14-05 Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-14-30 Low Residue Diet versus Clear Liquid Diet with Split Dose PEG-ELS for Colon Cleansing Prior to Colonoscopy, a Randomized Trial Open
UCI-14-58 Phase I, Multi-Center, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase II Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab, and Phase I Dose-Escalation Study of Enternally-Administered Marizomib with Bevacizumab Open
UCI-14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Open
UCI-14-86 Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System Open
UCI-14-89 [BIOREPOSITORY] Hematologic Malignancies Biorepository for human research Open
UCI-14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading Open
UCI-14-95 A Phase 1/2 Study of the Blinatumomab in Combination with the PD-1 Inhibitor Pembrolizumab (MK-3475) for the Treatment of Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia Open
UCI-14-96 A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma Open
UCI-15-18 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Open
UCI-15-20 A Pilot Study to Establish Proof-of-Concept that Patient-Specific Tumor Tissue Can Be Maintained in the Novel Tumor-on-a-Chip Model Open
UCI-15-35 A Phase II/III Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Open
UCI-15-40 [EXEMPT - REGISTRY TRIAL] Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma Open
UCI-15-52 A Phase III, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy Open
UCI-15-64 A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery Open
UCI-15-77 A Phase II Clinical Trial to study the efficacy and safety of pembrolizumab (MK-3475) in subjects with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy Open
UCI-15-79 Phase II Open-Label Randomized Study of Radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Open
UCI-15-80 A Phase III Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF /Thymidine Kinase-Deactivated Virus) Followed by Sorafenib versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy Open
UCI-15-81 Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma and Other Gastro-Intestinal Cancers with Liver-Only Metastasis Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-15-94 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-02 Breast and Cervical Cancer Survivorship in Zambia: Quality of Life, Social Support, and the Role of HIV/AIDS Open
UCI-16-100 A Phase II/III Multicenter, Open-label, Three-Arm, Two-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Open
UCI-16-19 A Randomized, Double-blind, Placebo-controlled Phase III Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy (ATLAS) Open
UCI-16-22 A Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Open
UCI-16-23 Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized versus Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] Open
UCI-16-29 Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization Open
UCI-16-31 [EXEMPT - RETROSPECTIVE] Importin &#945; is a Novel Biomarker of Barrett's Esophagus (BE)-Related Dysplasia & Cancer and Promotes Growth of BE-Derived Cancer Cells by Inducing Aberrant VEGF Expression Open
UCI-16-40 An Open-Label Multicenter Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Open
UCI-16-46 A Phase I dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias Open
UCI-16-50 A Phase Ib/II, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination with AZD9150 or AZD5069 in Patients with Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination with MEDI4736 as Second Line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Open
UCI-16-52 A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation Open
UCI-16-54 Identification of Functional MRI, Neuropsychiatric, and Circulating VEGF Changes After Marizomib Treatment in Patients Enrolled in the UCI 14-58 Study (Single Agent Marizomib Cohort) Open
UCI-16-55 Phase Ib, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma Open
UCI-16-57 Phase I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Open
UCI-16-69 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
UCI-16-70 Evaluation of Mitochondrial Priming in T Cell Lymphomas Open
UCI-16-72 A Randomized Double-Blind Phase III Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
UCI-16-74 A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine Open
UCI-16-77 Identification of Features Associated with Dysplasia Using the NvisionVLE® Imaging System Pilot Trial Open
UCI-16-81 Prospective Randomized Trial Comparing Trans-Arterial Chemoembolization Outcome Using Cone Beam CT vs. Conventional Fluoroscopy Open
UCI-16-82 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 Open
UCI-16-84 A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy Open
UCI-16-88 Development of Esophageal and Gastric Cancer Patient Derived Xenograft Mouse Models to Investigate Chemotherapy Resistance and Tumor Cell Response Open
UCI-16-94 Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti- PD-1 Monoclonal Antibody Open
UCI-16-95 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies Open
UCI-16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-05 Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing Open
UCI-17-07 Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment Open
UCI-17-08 Peripheral Hormonal Profile in Women with Breast Lesions Open
UCI-17-100 A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET mutated thyroid cancer Open
UCI-17-101 A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) Open
UCI-17-103 MM-398-07-02-03: A Randomized, Open-label Phase 2 Study of Irinotecan liposomal injection (lip-IRI)-containing Regimens versus nab-paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma Open
UCI-17-107 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Open
UCI-17-111 A Phase III, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer Open
UCI-17-114 A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (AZA) With or Without Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia Open
UCI-17-115 Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma Open
UCI-17-12 Optimization of Magnetic Resonance Imaging Applications on the 1.5 and 3.0 Tesla for Cardiovascular and Pulmonary Systems Open
UCI-17-18 A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy Open
UCI-17-19 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies Open
UCI-17-22 Epigenetic Markers for Pesticide Exposure and Cancer Risk Open
UCI-17-27 A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma Open
UCI-17-28 Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma Open
UCI-17-31 An Open-Label Phase II Study of Itacitinib (INCB039110) in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis Open
UCI-17-35 A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy Open
UCI-17-36 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma Open
UCI-17-39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation Open
UCI-17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response Open
UCI-17-43 Blood Collection Protocol for Circulating Tumor Cells, Circulating Cancer Associated Fibroblasts and Tissue Factor in Breast Cancer Patients Open
UCI-17-47 A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies Open
UCI-17-48 A Multinational Phase III, Randomized, Open-label, Parallelgroup Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer (HERO) Open
UCI-17-61 [EXEMPT - RETROSPECTIVE CHART REVIEW] Retrospective survival analysis among patients with non-small cell lung cancer harboring MET exon 14 mutations Open
UCI-17-70 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma Open
UCI-17-72 Evaluating the microbiome in myeloproliferative neoplasm Open
UCI-17-73 A Sequential 2-arm, Open-label Phase I Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors Open
UCI-17-76 Variations in Local Microbiome Populations in Normal Colorectal Tissue and Polyps Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-17-82 A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA Open
UCI-17-83 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer Open
UCI-17-84 Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) with Laparoscopic Assistance for Rectal Cancer Open
UCI-17-86 Phase I Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy Open
UCI-17-88 Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Open
UCI-17-89 A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma Open
UCI-17-90 A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy Open
UCI-17-92 TATE versus TACE, an Open-Label Randomized Study Comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma Open
UCI-17-95 UCI Chao Family Comprehensive Cancer Center Vietnamese Outreach to Improve Cancer Outcomes Open
UCI-17-96 A Prospective Single Arm Multicenter Study Evaluating the Effects of Spray Cryotherapy in Patients with Persistent Local Esophageal Cancer Open
UCI-17-97 A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) Open
UCI-18-06 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment Open
UCI-18-09 A Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Open
UCI-18-18 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) Open
UCI-18-24 A Multi-Center Prospective Comparison of Intracorporeal and Extracorporeal Anastomosis for Minimally Invasive Right Colectomy Protocol # ISI-dVRC-002 Open
UCI-18-29 Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma Open
UCI-95-29 Measurement of Breast Tissue Optical Properties Open
UCI-98-41 Outcomes and Assessment of Prostate Cancer at UCIMC Open